68Ga-R8760 Imaging for Adrenocortical Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging agent, 68Ga-R8760, to determine its safety and effectiveness in detecting adrenocortical cancer, a rare cancer of the adrenal gland. Researchers aim to understand how this agent behaves in the body and whether it aids in accurate diagnosis. Individuals with diagnosed adrenocortical carcinoma, particularly those with a measurable tumor, may be suitable for the study. Healthy volunteers are also needed to help assess the imaging agent's effects. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new imaging agent.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are using glucocorticoid steroids (including topical), you must stop at least 4 weeks before the study starts.
Is there any evidence suggesting that 68Ga-R8760 is likely to be safe for humans?
Research shows that specific safety information for 68Ga-R8760 is not yet available. However, compounds like 68Ga are often used in medical imaging and are generally well-tolerated. This study is in its early stages, with the primary goal of determining the safety of 68Ga-R8760 for people. Early studies focus on safety, so researchers will closely monitor any side effects.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about 68Ga-R8760 for adrenocortical cancer because it introduces a novel imaging approach. Unlike traditional treatments that focus on surgery, chemotherapy, or radiation, 68Ga-R8760 uses a radiotracer to help visualize cancerous tissues more precisely. This can potentially lead to better-targeted therapies and improved outcomes for patients. By enhancing the accuracy of imaging, this technique could change how doctors diagnose and monitor this rare cancer.
What evidence suggests that 68Ga-R8760 might be an effective treatment for adrenocortical cancer?
Research has shown that 68Ga-R8760 is a new imaging tool that can help detect cancer in people with adrenocortical carcinoma. This tool attaches to a specific part of the cancer cells called MC2R, often present in these cells. It helps doctors see the cancer more clearly during PET scans, which are special imaging tests. Although researchers are still studying 68Ga-R8760, its ability to identify cancer cells makes it a promising option for better diagnosing and treating this rare and aggressive cancer. Participants in this trial will join either the dose selection phase or the expansion cohort to further evaluate the effectiveness of 68Ga-R8760.24567
Are You a Good Fit for This Trial?
This trial is for adults with a BMI of 18-32 and adrenocortical carcinoma (ACC), either newly diagnosed or recurrent, who have at least one measurable lesion. They must be in relatively good health (ECOG ≤2) and have proper liver and kidney function. Participants need to agree to use contraception if applicable, understand the study, and sign consent forms. Exclusions include recent strokes, surgeries, acute illnesses, unstable heart conditions, other cancers that could affect results, certain infections like HIV or hepatitis B/C.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Selection
Participants receive varying doses of 68Ga-R8760 to determine optimal dosing
Expansion Cohort
Participants receive the selected dose of 68Ga-R8760 for further safety and dosimetry evaluation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 68Ga-R8760
Find a Clinic Near You
Who Is Running the Clinical Trial?
Radionetics Oncology
Lead Sponsor